Status:
TERMINATED
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
Lead Sponsor:
King's College London
Collaborating Sponsors:
Assistance Publique - Hôpitaux de Paris
University of Ulm
Conditions:
Multiple System Atrophy
Progressive Supranuclear Palsy
Eligibility:
All Genders
30-80 years
Phase:
PHASE3
Brief Summary
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed w...
Detailed Description
Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) often present as akinetic-rigid syndromes and in the early stages are difficult to differentiate in the clinic. Current Consensus...
Eligibility Criteria
Inclusion
- akinetic rigid syndrome plus clinical criteria for MSA or PSP
Exclusion
- Idiopathic Parkinson's disease
- Other neurological or serious medical disorders
- Unable to give informed consent
- dementia
- liver damage
- women of child bearing age unable to use effective method of contraception
Key Trial Info
Start Date :
April 1 2000
Trial Type :
INTERVENTIONAL
End Date :
November 1 2004
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00211224
Start Date
April 1 2000
End Date
November 1 2004
Last Update
December 15 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Psychiatry, King's College London
London, London, United Kingdom, SE58AF